Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 16/20 | 0.80 |
| ▸ | MMP2 | P08253 | 12/20 | 0.80 |
| ▸ | MMP13 | P45452 | 10/20 | 0.80 |
| ▸ | MMP9 | P14780 | 6/20 | 0.80 |
| ▸ | MMP3 | P08254 | 5/20 | 0.80 |
| ▸ | MMP1 | P03956 | 4/20 | 0.80 |
| ▸ | MMP7 | P09237 | 4/20 | 0.80 |
| ▸ | MMP8 | P22894 | 4/20 | 0.80 |
| ▸ | MMP14 | P50281 | 4/20 | 0.80 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.80 |
| ▸ | MMP15 | P51511 | 1/20 | 0.57 |
| ▸ | MMP16 | P51512 | 1/20 | 0.57 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8354979 | 0.91 | ADAM17 (0.82) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL6350415 | 0.89 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL6350418 | 0.89 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL1021287 | 0.89 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL29732231 | 0.89 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL4356730 | 0.88 | ADAM17 (0.86) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL7087215 | 0.84 | ADAM17 (0.76) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL6687471 | 0.83 | ADAM17 (0.79) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL4200591 | 0.83 | ADAM17 (0.87) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL13777102 | 0.83 | ADAM17 (0.87) | ADAM17MMP2MMP13MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232079-A1 | DPC 333 formulation having unique biopharmaceutical characteristics | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003082287-A1 | DPC 333 FORMULATION HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232079-A1 | DPC 333 formulation having unique biopharmaceutical characteristics | ADAM33, PTMA, TNF | ADAM17 9/4885MMP2 90/4885MMP13 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.